Abstract: A composition comprising an ethylene (meth)acrylic acid copolymer and an anti-fouling agent is provided. The composition selectively disintegrates in media of different ionic strengths. Also provided is a method of preventing fouling using the composition.
Type:
Grant
Filed:
September 25, 2014
Date of Patent:
September 3, 2019
Assignee:
Rohm and Haas Company
Inventors:
Scott Backer, Afia S. Karikari, Paul Mercando
Abstract: The invention relates to an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.
Abstract: A novel lipoteichoic acid (LTA) was isolated from C. difficile, the structure of which is illustrated below wherein n is an integer between 1 and 20, R3 and R4 are independently selected from C 14:0, C 16:0, C 16:1, C 18:0 or C18:1 fatty acid or any combination thereof wherein one of COR3 or COR4 may be replaced by H. Further described are conjugates comprising the novel LTA and vaccines produced using the isolated LTA and the LTA conjugates. The invention also encompasses methods of conferring immunity against C. difficile comprising administering a vaccine of the invention, and methods of detecting C. difficile using the isolated LTA of the invention.
Type:
Grant
Filed:
November 16, 2012
Date of Patent:
July 30, 2019
Assignee:
National Research Council of Canada
Inventors:
Christopher Reid, Susan M. Logan, Evguenii Vinogradov, Andrew Cox, Jean-Robert Brisson
Abstract: This disclosure relates to the engineering of phototrophic microorganisms for conversion of alkanes into higher-value products. Recombinant phototrophic organisms such as cyanobacteria can be engineered, optionally in a modular format, to express enzymes involved in converting methane to methanol, methanol to formaldehyde, formaldehyde to central metabolic pathway intermediates, and such intermediates to n-butanol.
Type:
Grant
Filed:
October 14, 2014
Date of Patent:
June 18, 2019
Assignee:
MOgene LC
Inventors:
Abhay Singh, Himadri Pakrasi, Ganesh M. Kishore
Abstract: Here we show that SEG/SEI presented from a HLA-DQ8 (HLA-DQB*0302 and HLA-DQA*0301) platform prevent the de novo outgrowth (vaccination) of Lewis lung carcinoma (LLC) and B16-F10 melanoma and retard the growth of established tumors with no significant toxicity. Vaccination of DQ8 tg mice with irradiated LLC or B16-F10 melanoma followed by SEG/SEI immunization and live tumor challenge resulted in 100 and 66% survival respectively for 200 days compared to a median survival of 20 days for untreated controls (p<0.001). In vaccination studies, DQ8 tg mice showed a surge in IFN? serum levels reaching 3000 fold above baseline devoid of a parallel spike in TNF? levels above baseline levels. Presentation of the SEG/SEI superantigen from a MHC-DQ8 platform, therefore, augments the therapeutic index of these SAgs inducing a tumoricidal response against Lewis lung carcinoma and B16 melanoma accompanied by a sharp increase of therapeutic IFN? levels absent toxic levels of TNF?.
Abstract: Provided are polyglyceryl compositions comprising one or more polyglyceryl compounds having: (a) a node structure comprising at least three contiguous glyceryl remnant units; (b) one or more cationic groups each linked to the node structure by an independently selected linking group; and (c) one or more hydrophobic moieties each independently (i) linked to the node structure by a linking group, or (ii) constituting a portion of one of the one or more cationic groups, wherein the composition has an average degree of polymerization determined by hydroxyl value testing (DPOH) of from about 3 to about 20. Also provided are polyglyceryl compounds which may compose such compositions, and uses of the polyglyceryl compositions and compounds.
Type:
Grant
Filed:
December 18, 2014
Date of Patent:
May 14, 2019
Assignee:
Johnson & Johnson Consumer Inc.
Inventors:
Michael J. Fevola, Frank C. Sun, Stacey E. York
Abstract: The invention provides vectors, attenuated pathogens, compositions, methods, and kits for use in preventing or treating infection by an infectious pathogen, especially Chlamydia trachomatis. The vectors comprise the plasmid encoded ppg genes from Chlamydia, ppg1, ppg2, ppg3, ppg5, ppg6, ppg7 and/or ppg8, but lack ppg4, a regulator of virulence associated genes. The application also provides attenuated pathogens, especially chlamydia, which are cured of their plasmid and have additional mutations to improve the attenuation, especially mutations in the CT135 gene or in the tryptophan operon (trp promoter, trpA, or trpB). Uses of said nucleic acids and attenuated pathogens for inducing or modulating an immune response in a subject, especially for prevention or treatment of infections, are proposed.
Type:
Grant
Filed:
January 16, 2014
Date of Patent:
April 16, 2019
Assignee:
The United States of America, as represented by the Secretary, Department of Health & Human Services
Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
Abstract: Recombinant attenuated Y. pseudotuberculosis mutants have been created that show efficacy as oral vaccines against plague caused by Y. pestis and Yersinosis caused by both Y. enterocolitica and Y. pseudotuberculosis. Thus, live attenuated Y. pseudotuberculosis-based vaccines can be used to prevent Yersinosis in farm animals such as swine, cattle and sheep. The palatable baits containing live attenuated Y. pseudotuberculosis-based vaccines may be acceptable methods to control plague epidemics in wild animals. The methods disclosed can also be used to generate recombinant attenuated Y. entercolitica and Y. pestis vaccine strains.
Type:
Grant
Filed:
September 10, 2015
Date of Patent:
March 12, 2019
Assignee:
Arizona Board of Regents on Behalf of Arizona State University
Abstract: Certain embodiments are directed to compositions comprising EHEC-specific antigens. In certain aspects EHEC O157:H7-specific antigen(s) are used as components of immunogenic compositions and vaccines.
Type:
Grant
Filed:
February 17, 2017
Date of Patent:
March 12, 2019
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXA SYSTEM
Abstract: The present invention provides an oligodeoxynucleotide containing humanized K type CpG oligodeoxynucleotide and poly deoxyadenylate, wherein the poly deoxyadenylate is placed on the 3?-side of the humanized K type CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing the aforementioned oligodeoxynucleotide and ?-1,3-glucan.
Type:
Grant
Filed:
September 19, 2014
Date of Patent:
February 12, 2019
Assignees:
NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION, DAIICHI SANKYO COMPANY, LIMITED
Abstract: The disclosure relates to a pharmaceutical formulation comprising hydrocortisone and its use in the treatment of conditions that would benefit from a delayed release of hydrocortisone, in particular conditions such as adrenal insufficiency, inflammatory conditions and depression.
Type:
Grant
Filed:
July 5, 2017
Date of Patent:
January 1, 2019
Assignee:
Diurnal Limited
Inventors:
Hiep Huatan, Richard Ross, Martin Whitaker
Abstract: A shaving cream formulation having one or more surfactants, one or more emulsifying agents, and water, wherein water is present in an amount of less than twenty weight percent based on total weight of the formulation. The shave cream formulation being compatible for use with a water-soluble film enclosure.
Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.
Abstract: A composition for human consumption includes a base composition having a pH of about 2 to about 5 and encapsulated caffeine dispersed throughout at least a portion of the base composition. The encapsulated caffeine can be a caffeine complex. The base composition can include a liquid or a food. An oral pouch product includes a porous pouch wrapper, an inner botanical filling material contained within the pouch wrapper, and encapsulated caffeine dispersed throughout at least a portion of the oral pouch product. The encapsulated caffeine is included in the composition and/or the oral pouch product an amount sufficient to release about 50 mg to about 200 mg of caffeine. The composition can provide immediate release of caffeine and/or release of caffeine over an extended period of time.
Abstract: The present invention provides an immune response modifier (IRM) composition that includes an IRM moiety and a second active moiety covalently linked to the IRM moiety, wherein the covalent link comprises a labile bond directly attached to the IRM moiety.
Type:
Grant
Filed:
June 25, 2018
Date of Patent:
December 4, 2018
Assignee:
3M Innovative Properties Company
Inventors:
Doris Stoermer, George W. Griesgraber, Tushar A. Kshirsagar
Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.
Abstract: The invention relates to medicine, and specifically to synthetic biologically active derivatives of carbopentoxysulfanilic acid. The novel substance comprises a (2,6-dichlorophenyl)amide salt of carbopentoxysulfanilic acid of general formula: Where X is Na, K, NH4; the drug may be contained in tablets, including sublingual tablets, or in capsules, or in suppositories, or in drops, or in mixtures, or in ointments, creams or other forms for application to the skin and mucosae, or in an oral-buccal film, or in a spray, or in a liquid for parenteral administration, or in chewing gum. A preparation having pronounced activity against herpes viruses is thus produced.
Type:
Grant
Filed:
December 23, 2016
Date of Patent:
October 16, 2018
Inventors:
Viktor Veniaminovich Tets, Georgy Viktorovich Tets